A BILL 
To establish a Federal strategy for preventing, diagnosing, 
and treating nonalcoholic steatohepatitis, commonly re-
ferred to as ‘‘NASH’’. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE; TABLE OF CONTENTS. 
3
(a) SHORT TITLE.—This Act may be cited as the 
4
‘‘Nonalcoholic Steatohepatitis Care Act of 2020’’ or the 
5
‘‘NASH Care Act of 2020’’. 
6
(b) TABLE OF CONTENTS.—The table of contents for 
7
this Act is as follows: 
8
Sec. 1. Short title; table of contents. 
Sec. 2. National prevention program for diabetes, nonalcoholic fatty liver dis-
ease, and metabolic syndrome. 
21:52 Nov 13, 2020
H8658
jbell on DSKJLSW7X2PROD with BILLS
2 
•HR 8658 IH
Sec. 3. Grants for community-based patient education and provider training 
and outreach. 
Sec. 4. National Academies of Sciences study on education and policy needs for 
nonalcoholic steatohepatitis and nonalcoholic fatty liver disease. 
Sec. 5. National surveillance program for nonalcoholic fatty liver disease and 
nonalcoholic steatohepatitis. 
Sec. 6. Recommendations for the prevention, screening, diagnosis, and treat-
ment of interrelated conditions developed by multidisciplinary 
task force. 
Sec. 7. Renaming of NIH institute to reflect liver diseases and creation of divi-
sion of liver diseases. 
SEC. 2. NATIONAL PREVENTION PROGRAM FOR DIABETES, 
1
NONALCOHOLIC FATTY LIVER DISEASE, AND 
2
METABOLIC SYNDROME. 
3
Section 399V–3 of the Public Health Service Act 
4
(280g–14) is amended— 
5
(1) in subsection (a)— 
6
(A) by inserting ‘‘or continue’’ after ‘‘es-
7
tablish’’; 
8
(B) by striking ‘‘national diabetes’’; 
9
(C) by inserting ‘‘, nonalcoholic fatty liver 
10
disease, and metabolic syndrome’’ after ‘‘high 
11
risk for diabetes’’; and 
12
(D) by striking ‘‘burden of diabetes’’ and 
13
inserting ‘‘such conditions’’; 
14
(2) in subsection (b)— 
15
(A) by striking paragraph (1) 
16
(B) 
by 
redesignating 
paragraphs 
(2) 
17
through (4) as paragraphs (3) through (5); and 
18
(C) by inserting before paragraph (3) (as 
19
so redesignated) the following; 
20
21:52 Nov 13, 2020
H8658
jbell on DSKJLSW7X2PROD with BILLS
3 
•HR 8658 IH
‘‘(1) competitive grants to eligible entities for 
1
the purposes of identifying, developing, or dissemi-
2
nating best practices on the prevention, detection, 
3
and treatment of diabetes, nonalcoholic fatty liver 
4
disease, and metabolic syndrome; 
5
‘‘(2) competitive grants for eligible entities for 
6
the development of community-based prevention pro-
7
gram model sites;’’; 
8
(3) by redesignating subsection (d) as sub-
9
section (e); 
10
(4) by inserting after subsection (c) the fol-
11
lowing: 
12
‘‘(d) PREFERENCE.—In awarding grants under sub-
13
section (b), the Secretary may give preference to eligible 
14
entities that— 
15
‘‘(1) provide lifestyle interventions, including 
16
nutrition and exercise consultation; and 
17
‘‘(2) serve racial and ethnic minority commu-
18
nities with high rates of diabetes, nonalcoholic fatty 
19
liver disease, and metabolic syndrome.’’ ; and 
20
(5) in subsection (e) (as redesignated by para-
21
graph (3)), by striking ‘‘such sums as may be nec-
22
essary for each of fiscal years 2010 through 2014’’ 
23
and inserting ‘‘$27,300,000 for each of fiscal years 
24
2021 through 2025’’. 
25
21:52 Nov 13, 2020
H8658
jbell on DSKJLSW7X2PROD with BILLS
4 
•HR 8658 IH
SEC. 3. GRANTS FOR COMMUNITY-BASED PATIENT EDU-
1
CATION AND PROVIDER TRAINING AND OUT-
2
REACH. 
3
(a) IN GENERAL.—The Secretary of Health and 
4
Human Services, acting through the Director of the Cen-
5
ters for Disease Control and Prevention, shall establish 
6
a grant program under which the Secretary may award 
7
grants to eligible entities to provide education in the pre-
8
vention of nonalcoholic steatohepatitis (referred to in this 
9
Act as ‘‘NASH’’), which shall be know as the National 
10
NASH Prevention and Education Program (referred to in 
11
this section as ‘‘the Program’’). To the extent practicable, 
12
the Secretary shall align such program with the eligibility 
13
criteria to receive grants under the National Diabetes Pre-
14
vention Program of the Centers for Disease Control and 
15
Prevention. 
16
(b) ELIGIBLE ENTITIES.—An entity is eligible to re-
17
ceived a grant under the Program if such entity— 
18
(1)(A) provides lifestyle interventions such as 
19
promotion of liver health interventions or nutrition 
20
and exercise consultation; or 
21
(B) serves racial and ethnic minority commu-
22
nities with high rates of nonalcoholic fatty liver dis-
23
ease (as determined by Secretary); and 
24
(2) is a community-based, nonprofit organiza-
25
tion located in any state or is an experienced organi-
26
21:52 Nov 13, 2020
H8658
jbell on DSKJLSW7X2PROD with BILLS
5 
•HR 8658 IH
zation in developing liver health education and 
1
awareness programs. 
2
(c) APPLICATION.—An eligible entity seeking a grant 
3
under this section shall submit an application to the Sec-
4
retary at such time, in such manner, and containing such 
5
information as the Secretary may require. 
6
(d) TERM.—The term of a grant awarded under this 
7
section shall not exceed 5 years. 
8
(e) CURRICULUM DEVELOPMENT.— 
9
(1) IN GENERAL.—The Secretary shall develop, 
10
taking into consideration the best practices devel-
11
oped by grantees under section 399V–3(b)(1) of the 
12
Public Health Service Act, as amended by section 2 
13
of this Act, directly or through grants to eligible en-
14
tities, a curriculum to provide education in NASH 
15
prevention for use by recipients of grants under this 
16
section. 
17
(2) FOCUS AREAS.—The curriculum shall pro-
18
vide for consistency in— 
19
(A) application of screening and diagnostic 
20
recommendations; 
21
(B) collection of population data and qual-
22
ity measures; and 
23
21:52 Nov 13, 2020
H8658
jbell on DSKJLSW7X2PROD with BILLS
6 
•HR 8658 IH
(C) delivery of recommended evidence- 
1
based lifestyle interventions specific to nutrition 
2
and exercise. 
3
(f) POPULATIONS CONSIDERED.—In carrying out 
4
this section, the Secretary shall consider the needs of pedi-
5
atric and minority populations at risk for NASH. 
6
(g) COORDINATION WITH CONTINUING MEDICAL 
7
EDUCATION.—The task force established under section 6 
8
shall, to the extent practicable, coordinate the availability 
9
of training and outreach under this subsection with the 
10
opportunity for providers receiving training pursuant to 
11
this section to earn continuing medical education credits. 
12
(h) AUTHORIZATION
OF APPROPRIATIONS.—There 
13
are authorized to be appropriated to carry out this section 
14
such sums as may be necessary for each of fiscal years 
15
2021 through 2025. 
16
SEC. 4. NATIONAL ACADEMIES OF SCIENCES STUDY ON 
17
EDUCATION AND POLICY NEEDS FOR NON-
18
ALCOHOLIC 
STEATOHEPATITIS 
AND 
NON-
19
ALCOHOLIC FATTY LIVER DISEASE. 
20
(a) IN GENERAL.—Not later than 180 days after the 
21
date of the enactment of this Act, the Secretary of Health 
22
and Human Services shall offer to enter into a contract 
23
with the National Academies of Sciences to conduct a 
24
21:52 Nov 13, 2020
H8658
jbell on DSKJLSW7X2PROD with BILLS
7 
•HR 8658 IH
study on nonalcoholic fatty liver disease and nonalcoholic 
1
steatohepatitis in the United States. 
2
(b) FOCUS AREAS.—The study conducted pursuant 
3
to subsection (a) shall focus on education and policy needs 
4
involving nonalcoholic fatty liver disease and nonalcoholic 
5
steatohepatitis, including— 
6
(1) opportunities to strengthen prevention of 
7
nonalcoholic fatty liver disease and nonalcoholic 
8
steatohepatitis, including through enhanced delivery 
9
of nutrition services; 
10
(2) barriers to diagnosis and treatment of non-
11
alcoholic 
fatty 
liver 
disease 
and 
nonalcoholic 
12
steatohepatitis, including opportunities to strengthen 
13
coverage under the Medicare program under title 
14
XVIII of the Social Security Act (42 U.S.C. 1395 et 
15
seq.), the Medicaid program under title XIX of such 
16
Act (42 U.S.C. 1396 et seq.), group health plans (as 
17
defined in section 2791 of the Public Health Service 
18
Act (42 U.S.C. 300gg–91)), and group or individual 
19
health insurance coverage (as such terms are defined 
20
in such section 2791); 
21
(3) recommendations for enhancing provider 
22
education on nonalcoholic fatty liver disease and 
23
nonalcoholic steatohepatitis; and 
24
21:52 Nov 13, 2020
H8658
jbell on DSKJLSW7X2PROD with BILLS
8 
•HR 8658 IH
(4) recommendations for enhancing patient 
1
awareness of nonalcoholic fatty liver disease and 
2
nonalcoholic steatohepatitis, including early identi-
3
fication of risk factors and linkage to appropriate 
4
care. 
5
(c) REPORT.—The agreement entered into under sub-
6
section (a) shall require the National Academies of 
7
Sciences to, not later than January 1, 2022, submit a re-
8
port on the findings of the study to the Secretary and the 
9
Chairman and Ranking Member of each of the following 
10
committees: 
11
(1) The Committee on Energy and Commerce 
12
of the House of Representatives. 
13
(2) The Committee on Ways and Means of the 
14
House of Representatives. 
15
(3) The Committee on Finance of the Senate. 
16
(4) The Committee on Health, Education, 
17
Labor, and Pensions of the Senate. 
18
(d) AUTHORIZATION
OF APPROPRIATIONS.—There 
19
are authorized to be appropriated to carry out this section 
20
$1,000,000 for each of fiscal years 2021 and 2022. 
21
21:52 Nov 13, 2020
H8658
jbell on DSKJLSW7X2PROD with BILLS
9 
•HR 8658 IH
SEC. 5. NATIONAL SURVEILLANCE PROGRAM FOR NON-
1
ALCOHOLIC FATTY LIVER DISEASE AND NON-
2
ALCOHOLIC STEATOHEPATITIS. 
3
(a) IN GENERAL.—The Secretary of Health and 
4
Human Services, acting through the Director of the Cen-
5
ters for Disease Control and Prevention, shall establish 
6
a program to provide for surveillance on the prevalence 
7
of nonalcoholic fatty liver disease and nonalcoholic 
8
steatohepatitis in the United States. 
9
(b) PROGRAM ACTIVITIES.— 
10
(1) SURVEILLANCE ACTIVITIES.—The program 
11
established under subsection (a) shall include, at a 
12
minimum, each of the following surveillance activi-
13
ties: 
14
(A) Conducting local surveillance activities 
15
to collect data on the prevalence and severity of 
16
nonalcoholic fatty level disease and nonalcoholic 
17
steatohepatitis. 
18
(B) Compiling and annually publishing 
19
data on the number of individuals with non-
20
alcoholic fatty level disease and nonalcoholic 
21
steatohepatitis nationally as well as in each 
22
state. 
23
(C) To the extent practicable, providing 
24
data on the general population at risk of devel-
25
oping the conditions. 
26
21:52 Nov 13, 2020
H8658
jbell on DSKJLSW7X2PROD with BILLS
10 
•HR 8658 IH
(2) TECHNICAL ASSISTANCE ON VITAL STATIS-
1
TICS.—In carrying out the program under sub-
2
section (a), the Secretary of Health and Human 
3
Services, acting through the Director of the Centers 
4
for Disease Control and Prevention, shall issue guid-
5
ance that provides technical assistance to health care 
6
providers and State and local health departments on 
7
best practices to ensure appropriate collection of 
8
vital statistics for purposes of birth and death cer-
9
tificates, including vital statistics on populations 
10
with nonalcoholic fatty level disease and nonalcoholic 
11
steatohepatitis. 
12
(c) AUTHORIZATION
OF APPROPRIATIONS.—There 
13
are authorized to be appropriated— 
14
(1) to carry out surveillance activities described 
15
in subsection (b)(1), $10,000,000 for each of fiscal 
16
years 2021 and 2022; 
17
(2) to carry out technical assistance activities 
18
described in subsection (b)(3), $10,000,000 for each 
19
of fiscal years 2021 and 2022; and 
20
(3) to carry out the activities described in sub-
21
section (b)(2), $5,000,000 for each of fiscal years 
22
2021 through 2025. 
23
21:52 Nov 13, 2020
H8658
jbell on DSKJLSW7X2PROD with BILLS
11 
•HR 8658 IH
SEC. 
6. 
RECOMMENDATIONS 
FOR 
THE 
PREVENTION, 
1
SCREENING, DIAGNOSIS, AND TREATMENT OF 
2
INTERRELATED CONDITIONS DEVELOPED BY 
3
MULTIDISCIPLINARY TASK FORCE. 
4
(a) IN GENERAL.—Not later than 180 days after the 
5
date of the enactment of this Act, the Secretary of Health 
6
and Human Services shall establish a multidisciplinary 
7
task force, and appoint members to such task force, to 
8
develop recommendations for the prevention, screening, di-
9
agnosis, and treatment for several interrelated conditions, 
10
including, at a minimum— 
11
(1) nonalcoholic fatty liver disease; 
12
(2) nonalcoholic steatohepatitis; 
13
(3) obesity; 
14
(4) diabetes and other metabolic disorders; and 
15
(5) any other conditions determined appropriate 
16
by the Secretary. 
17
(b) MEMBERSHIP.—The task force established under 
18
subsection (a) shall be composed of not more than 12 
19
members to be appointed by the Secretary and shall in-
20
clude representatives of each of the following groups: 
21
(1) 
Physician 
specialists, 
including 
in 
22
hepatology, gastroenterology, endocrinology, cardi-
23
ology, and endocrinology. 
24
(2) Experts in public health and epidemiology. 
25
(3) Patient advocates. 
26
21:52 Nov 13, 2020
H8658
jbell on DSKJLSW7X2PROD with BILLS
12 
•HR 8658 IH
(4) Non-voting representatives of Federal agen-
1
cies, including the Food and Drug Administration, 
2
the National Institutes of Health, the Centers for 
3
Disease Control and Prevention, and the Office of 
4
the Assistant Secretary for Health of the Depart-
5
ment of Health and Human Services. 
6
(5) Non-voting representatives of manufactur-
7
ers of drugs, devices, or diagnostic tools approved by 
8
the Food and Drug Administration for the treat-
9
ment of any of the conditions specified in subsection 
10
(a). 
11
(c) DEVELOPMENT OF RECOMMENDATIONS.—In de-
12
veloping the recommendations under subsection (a), the 
13
task force established under such subsection shall con-
14
sider— 
15
(1) guidelines issued by the American Associa-
16
tion for the Study of Liver Diseases, published evi-
17
dence, recommendations of the United States Pre-
18
ventive Services Task Force, and other information 
19
it determines appropriate in developing such rec-
20
ommendations; and 
21
(2) whether a combined protocol addressing a 
22
range of conditions specified in such subsection is 
23
advised for populations affected by more than one 
24
21:52 Nov 13, 2020
H8658
jbell on DSKJLSW7X2PROD with BILLS
13 
•HR 8658 IH
condition for which such recommendations are being 
1
developed. 
2
(d) DEADLINE
FOR
COMPILING
RECOMMENDA-
3
TIONS.—The task force shall compile screening and diag-
4
nosis recommendations developed under subsection (a) not 
5
later than 18 months after the date on which the first 
6
meeting of the task force concludes. 
7
(e) PUBLIC HEALTH ACTION PLAN.— 
8
(1) IN GENERAL.—Not later than 1 year after 
9
the date of the enactment of this Act, the task force 
10
shall develop an action plan to combat nonalcoholic 
11
steatohepatitis (referred to in this section as ‘‘the 
12
Action Plan’’). 
13
(2) ISSUES
ADDRESSED.—The Action Plan 
14
shall identify key goals and implementation strate-
15
gies for— 
16
(A) assuring appropriate surveillance of 
17
the public health impact in the United States of 
18
nonalcoholic steatohepatitis; 
19
(B) increasing awareness among the gen-
20
eral public of the United States of risk factors; 
21
(C) enhancing clinical education on the 
22
prevention, diagnosis, and treatment of non-
23
alcoholic steatohepatitis among physicians and 
24
21:52 Nov 13, 2020
H8658
jbell on DSKJLSW7X2PROD with BILLS
14 
•HR 8658 IH
health care professionals within the United 
1
States; 
2
(D) supporting research on therapies and 
3
cures for nonalcoholic steatohepatitis; and 
4
(E) other areas determined appropriate by 
5
the Secretary. 
6
(3) EVALUATION AND REPORT.— 
7
(A) EVALUATION.—The Secretary shall, at 
8
least every 2 years, evaluate the implementation 
9
of the Action Plan under this section to provide 
10
any updates or modifications to such plan. 
11
(B) REPORT.—Not later than 18 months 
12
after the date on which the Action Plan devel-
13
oped under paragraph (1) is released, the Sec-
14
retary shall submit to Congress a report that 
15
discusses any updated recommendations for up-
16
dates 
or 
modifications 
considering 
initial 
17
progress made in advancing the action plan’s 
18
goals or barriers to attaining such goals. 
19
(f) REPORT REGARDING LIVER CANCER.—Not later 
20
than 1 year after the date on which the first meeting of 
21
the working group is held, the working group shall trans-
22
mit to the Director of the NIH a report providing rec-
23
ommendations with respect to preventive and diagnostic 
24
measures that could, in consideration of the relationship 
25
21:52 Nov 13, 2020
H8658
jbell on DSKJLSW7X2PROD with BILLS
15 
•HR 8658 IH
between the prevalence of liver cancer and the prevalence 
1
of certain liver diseases, help reduce liver cancer rates and 
2
make liver cancer more treatable when detected. 
3
SEC. 7. RENAMING OF NIH INSTITUTE TO REFLECT LIVER 
4
DISEASES AND CREATION OF DIVISION OF 
5
LIVER DISEASES. 
6
(a) INSTITUTE RENAMED.—Effective on January 1, 
7
2021, title IV of the Public Health Service Act is amended 
8
by striking ‘‘National Institute for Diabetes and Digestive 
9
and Kidney Diseases’’ each place it appears in section 
10
401(b) (42 U.S.C. 281(b)), in section 409A(a) (42 U.S.C. 
11
284a(a)), in the heading of subpart 3 of part C, in section 
12
426 (42 U.S.C. 285c), and section 430 (42 U.S.C. 285c– 
13
4) and inserting ‘‘The National Institute of Diabetes and 
14
Digestive, Kidney, and Liver Diseases’’. 
15
(b) CONFORMING CHANGES.—Effective on January 
16
1, 2021, any reference to the National Institute for Diabe-
17
tes and Digestive and Kidney Diseases in any law, regula-
18
tion, document, record, or other paper of the United 
19
States shall be deemed to be a reference to the National 
20
Institute of Diabetes and Digestive, Kidney, and Liver 
21
Diseases. 
22
(c) ESTABLISHMENT OF DIVISION FOR LIVER DIS-
23
EASES.— 
24
21:52 Nov 13, 2020
H8658
jbell on DSKJLSW7X2PROD with BILLS
16 
•HR 8658 IH
(1) IN GENERAL.—Section 428 of the Public 
1
Health Service Act (42 U.S.C. 285c–2) is amend-
2
ed— 
3
(A) in subsection (a)(1)— 
4
(i) in the matter preceding subpara-
5
graph (A), by inserting ‘‘a Division Direc-
6
tor for Liver Diseases,’’ after ‘‘and Nutri-
7
tion,’’; and 
8
(ii) in subparagraph (A), by inserting 
9
‘‘liver diseases,’’ after ‘‘and nutrition,’’; 
10
and 
11
(B) in subsection (b)— 
12
(i) in the matter preceding paragraph 
13
(1), by inserting ‘‘the Division Director for 
14
Liver Diseases,’’ after ‘‘and Nutrition,’’; 
15
and 
16
(ii) in paragraph (1), by inserting 
17
‘‘liver diseases,’’ after ‘‘and nutritional dis-
18
orders,’’. 
19
(2) TRANSFER
OF
AUTHORITY.—Effective on 
20
January 1, 2021, the Secretary of Health and 
21
Human Services, acting through the Director of the 
22
National Institutes of Health, shall transfer to the 
23
Division Director of Liver Diseases of the National 
24
Institute of Diabetes and Digestive, Kidney, and 
25
21:52 Nov 13, 2020
H8658
jbell on DSKJLSW7X2PROD with BILLS
17 
•HR 8658 IH
Liver Diseases, the authorities (including all budget 
1
authorities, available appropriations, and personnel), 
2
duties, obligations, and related legal and administra-
3
tive functions prescribed by law or otherwise pre-
4
viously granted to the Liver Disease Research 
5
Branch within the Division of Digestive Diseases 
6
and Nutrition of the National Institute for Diabetes 
7
and Digestive and Kidney Diseases. 
8
Æ 
21:52 Nov 13, 2020
H8658
jbell on DSKJLSW7X2PROD with BILLS
